ArticleNature cardiovascular research2026

Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy.

Laura Sen-Martín et al.PubMed ↗Publisher ↗

No numbers read from the abstract.